ASBP
Price
$0.36
Change
-$0.03 (-7.69%)
Updated
Aug 15 closing price
Capitalization
N/A
ERAS
Price
$1.64
Change
+$0.07 (+4.46%)
Updated
Aug 15 closing price
Capitalization
465.22M
80 days until earnings call
Interact to see
Advertisement

ASBP vs ERAS

Header iconASBP vs ERAS Comparison
Open Charts ASBP vs ERASBanner chart's image
Aspire Biopharma Holdings
Price$0.36
Change-$0.03 (-7.69%)
Volume$308.55K
CapitalizationN/A
Erasca
Price$1.64
Change+$0.07 (+4.46%)
Volume$456.87K
Capitalization465.22M
ASBP vs ERAS Comparison Chart in %
Loading...
ASBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASBP vs. ERAS commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASBP is a Hold and ERAS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (ASBP: $0.36 vs. ERAS: $1.64)
Brand notoriety: ASBP and ERAS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASBP: 8% vs. ERAS: 54%
Market capitalization -- ASBP: $0 vs. ERAS: $465.22M
ASBP [@Biotechnology] is valued at $0. ERAS’s [@Biotechnology] market capitalization is $465.22M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASBP’s FA Score shows that 1 FA rating(s) are green whileERAS’s FA Score has 1 green FA rating(s).

  • ASBP’s FA Score: 1 green, 4 red.
  • ERAS’s FA Score: 1 green, 4 red.
According to our system of comparison, ERAS is a better buy in the long-term than ASBP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ASBP’s TA Score shows that 3 TA indicator(s) are bullish while ERAS’s TA Score has 6 bullish TA indicator(s).

  • ASBP’s TA Score: 3 bullish, 5 bearish.
  • ERAS’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ERAS is a better buy in the short-term than ASBP.

Price Growth

ASBP (@Biotechnology) experienced а +6.85% price change this week, while ERAS (@Biotechnology) price change was +17.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

ERAS is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ERAS YTD gains are higher at: -34.661 vs. ASBP (-96.878).
ASBPERASASBP / ERAS
CapitalizationN/A465M-
EBITDAN/A-150.24M-
Gain YTD-96.878-34.661279%
P/E RatioN/AN/A-
RevenueN/A0-
Total CashN/A305M-
Total DebtN/A50.8M-
TECHNICAL ANALYSIS
Technical Analysis
ASBPERAS
RSI
ODDS (%)
Bearish Trend 3 days ago
18%
Bearish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
44%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
25%
Bullish Trend 3 days ago
80%
MACD
ODDS (%)
Bearish Trend 3 days ago
19%
Bullish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
36%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
37%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 7 days ago
39%
Bullish Trend 5 days ago
79%
Declines
ODDS (%)
Bearish Trend 3 days ago
64%
Bearish Trend 17 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
20%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 3 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ASBP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ERAS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME22.940.05
+0.22%
GameStop Corp
BTC.X117491.35000093.000000
+0.08%
Bitcoin cryptocurrency
SPY643.44-1.51
-0.23%
SPDR® S&P 500® ETF
AAPL231.59-1.19
-0.51%
Apple
TSLA330.56-5.02
-1.50%
Tesla

ASBP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASBP has been loosely correlated with SPRO. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ASBP jumps, then SPRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASBP
1D Price
Change %
ASBP100%
-7.83%
SPRO - ASBP
58%
Loosely correlated
-3.54%
ALZN - ASBP
30%
Poorly correlated
-2.26%
ORIC - ASBP
29%
Poorly correlated
-2.72%
ERAS - ASBP
29%
Poorly correlated
+4.46%
BRNS - ASBP
26%
Poorly correlated
-2.81%
More